Edition:
United States

Inovio Pharmaceuticals Inc (INO.OQ)

INO.OQ on NASDAQ Stock Exchange Global Select Market

4.24USD
2:32pm EST
Change (% chg)

$0.05 (+1.32%)
Prev Close
$4.18
Open
$4.18
Day's High
$4.26
Day's Low
$4.12
Volume
123,014
Avg. Vol
286,770
52-wk High
$9.85
52-wk Low
$3.77

Chart for

About

Inovio Pharmaceuticals, Inc. (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company's DNA-based immunotherapies, in combination with its electroporation delivery... (more)

Overall

Beta: 2.51
Market Cap(Mil.): $377.44
Shares Outstanding(Mil.): 90.30
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 192.73 16.31
EPS (TTM): -- -- --
ROI: -- -0.67 35.74
ROE: -- -3.38 17.71

BRIEF-Inovio Pharmaceuticals, Parker Institute For Cancer Immunotherapy Establish Clinical Development Collaboration To Evaluate Novel Cancer Immunotherapy Combinations

* INOVIO PHARMACEUTICALS AND THE PARKER INSTITUTE FOR CANCER IMMUNOTHERAPY ESTABLISH CLINICAL DEVELOPMENT COLLABORATION TO EVALUATE NOVEL CANCER IMMUNOTHERAPY COMBINATIONS

Jan 09 2018

BRIEF-Inovio Receives Milestone Payment From Medimmune

* INOVIO RECEIVES MILESTONE PAYMENT FROM MEDIMMUNE AS MEDI0457 AND CHECKPOINT INHIBITOR COMBINATION TRIAL IN HEAD AND NECK SQUAMOUS CELL CANCER ADVANCES TO PHASE 2 Source text for Eikon: Further company coverage:

Jan 08 2018

BRIEF-Inovio Enters License, Collaboration Agreement With Apollobio To Develop, Commercialize VGX-3100 In Greater China

* INOVIO ENTERS LICENSE AND COLLABORATION AGREEMENT WITH APOLLOBIO TO DEVELOP AND COMMERCIALIZE VGX-3100 IN GREATER CHINA

Jan 02 2018

BRIEF-‍Inovio Pharma Cancer Vaccine Shows Promise In Preclinical Trial

* ‍INOVIO PHARMACEUTICALS SYNCON TERT CANCER IMMUNOTHERAPY COMBINED WITH CHECKPOINT INHIBITOR SYNERGISTICALLY SHRINKS TUMOR,IMPROVES SURVIVAL IN PRECLINICAL TUMOR MODEL​ Source text for Eikon: Further company coverage:

Nov 27 2017

BRIEF-Inovio pharmaceuticals reports 2017 third quarter financial results

* Inovio Pharmaceuticals reports 2017 third quarter financial results

Nov 08 2017

BRIEF-Inovio Pharma says ‍on Oct 30, Apollobio board approved agreements of license & collaboration agreement with co which was announced on July 14

* Inovio Pharmaceuticals says ‍on Oct 30, Apollobio board approved agreements of license & collaboration agreement with co which was announced on July 14

Nov 02 2017

BRIEF-Inovio Pharma initiates immuno-oncology clinical study for glioblastoma

* Inovio Pharmaceuticals initiates immuno-oncology clinical study for glioblastoma in combination with Regeneron’S PD-1 inhibitor Source text for Eikon: Further company coverage:

Nov 01 2017

BRIEF-Inovio Pharmaceuticals reports positive results from phase 1 trial of zika virus vaccine

* Inovio Pharmaceuticals Inc ‍reported on positive safety and immune response results from phase 1 trial of a vaccine against zika virus​

Oct 05 2017

BRIEF-Inovio and partners initiate Phase 1/2A clinical trial to further advance its vaccine against deadly MERS infection

* Inovio and partners initiate Phase 1/2A clinical trial to further advance its vaccine against deadly MERS infection

Sep 18 2017

BRIEF-Inovio’s cancer immunotherapy slowed PSA rise and increased PSA doubling times in patients with recurrent prostate cancer

* Inovio’s cancer immunotherapy (ino-5150) slowed PSA rise and significantly increased psa doubling times in patients with recurrent prostate cancer

Sep 11 2017

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $130.81 +0.90
Novartis AG (NOVN.S) CHF79.38 -0.60
Pfizer Inc. (PFE.N) $36.03 +0.29
Merck & Co., Inc. (MRK.N) $54.84 +0.27
Sanofi SA (SASY.PA) €65.05 +0.16
GlaxoSmithKline plc (GSK.L) 1,296.00 -7.00
AstraZeneca plc (AZN.L) 4,752.00 -20.00

Earnings vs. Estimates